23 Own capitalized costs
Own capitalized costs amounted to EUR 2.7 billion in the reporting year (2022: EUR 2.9 billion, 2021: EUR 2.8 billion) and mainly relate to investments in network build-out and the development of platforms for cell sites.
Own capitalized costs amounted to EUR 2.7 billion in the reporting year (2022: EUR 2.9 billion, 2021: EUR 2.8 billion) and mainly relate to investments in network build-out and the development of platforms for cell sites.